Cagrilintide
An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus.
Cagrilintide: An appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus. Cagrilintide is an amylin agonist, a different appetite-control pathway than the GLP-1 drugs.
Cagrilintide is an amylin agonist, a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.
Investigational. Phase 3 trials by Novo Nordisk, often paired with semaglutide as 'CagriSema'.
Not yet approved. Trial access only.
Who it's for
- →Users plateaued on Semaglutide or Tirzepatide
- →People wanting cleaner satiety without bigger GLP-1 nausea
- →Combination-therapy stacks under provider guidance
What to expect
- Week 1
Mild appetite drop. Less nausea than the GLP-1 drugs.
- Week 4
First titration step. Modest weight loss alone, stronger when stacked with semaglutide.
- Week 8
Steady-state. Best results in 'CagriSema' combination with semaglutide.
Looking at Cagrilintide? Your next 3 steps
- 1Work out your exact dose
Vial size + BAC water turns into the exact units to draw for Cagrilintide.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account saves your stack; membership adds the stack-aware AI Coach.
Create free account →
How it works (mechanism)
Long-acting amylin agonist. Binds amylin receptors (also calcitonin receptor crosstalk) to slow gastric emptying and increase satiety through a different pathway than GLP-1. Pairs naturally with Semaglutide as 'CagriSema.'
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠History of medullary thyroid carcinoma or MEN-2
- ⚠Pancreatitis history
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • A1C if metabolic context
- • Lipid panel
Common mistakes
- • Expecting standalone results to match Tirzepatide (it won't)
- • Titrating too fast
- • Skipping protein during the cut
Drug & supplement interactions
- ⚠Slows gastric emptying, affects oral medication absorption
- ⚠Pairs intentionally with Semaglutide; combined nausea profile
Community patterns
New to Cagrilintide? Grab the starter checklist.
Drop your email and we'll send the one-page first-cycle starter checklist, plus a heads-up if Cagrilintide changes legal status. No account needed.
No spam. No selling your email. Just the checklist and the occasional reclassification alert.
Ask the Coach anything about Cagrilintide or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Get the Coach, $7.99/mo →Frequently asked
What is Cagrilintide?+
Is Cagrilintide FDA approved?+
Is Cagrilintide legal?+
Is Cagrilintide banned by WADA?+
Are you still natty after taking Cagrilintide?+
Do doctors prescribe Cagrilintide?+
What's the typical dose of Cagrilintide?+
What are the side effects of Cagrilintide?+
How long until Cagrilintide starts working?+
What can you stack with Cagrilintide?+
Where do people get Cagrilintide?+
Cagrilintide vs Semaglutide, which is better?+
Cagrilintide vs Tirzepatide, which is better?+
Head-to-head with Cagrilintide
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.